Researchers from Tohoku University launched the study in 1986 under Professor Yutaka Imai in response to the high burden of hypertension and stroke in Ohasama, Iwate Prefecture.
Regulators approved the drug as an additional therapy for patients whose blood pressure remains uncontrolled despite using standard antihypertensive medicines.